{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T16:44:26Z","timestamp":1784133866134,"version":"3.55.0"},"reference-count":141,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.autrev.2025.103894","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T22:59:21Z","timestamp":1754434761000},"page":"103894","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Points to consider in the management of ANCA-associated vasculitis"],"prefix":"10.1016","volume":"24","author":[{"given":"Marina","family":"Papadopoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Karamanakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.autrev.2025.103894_bb0005","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.autrev.2025.103894_bb0010","first-page":"160","article-title":"KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis published correction appears in Kidney","volume":"106","author":"Kidney Disease: Improving Global Outcomes (KDIGO) ANCA Vasculitis Work Group","year":"2024","journal-title":"Int"},{"issue":"8","key":"10.1016\/j.autrev.2025.103894_bb0015","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.autrev.2025.103894_bb0020","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.autrev.2025.103894_bb0025","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"European Vasculitis study group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.autrev.2025.103894_bb0030","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1681\/ASN.2019111197","article-title":"Efficacy of rituximab and plasma exchange in Antineutrophil cytoplasmic antibody-associated Vasculitis with severe kidney Disease","volume":"31","author":"Casal Moura","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"issue":"2","key":"10.1016\/j.autrev.2025.103894_bb0035","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40620-015-0208-y","article-title":"Rituximab for treatment of severe renal disease in ANCA associated vasculitis","volume":"29","author":"Geetha","year":"2016","journal-title":"J Nephrol"},{"issue":"9","key":"10.1016\/j.autrev.2025.103894_bb0040","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.42515","article-title":"Comparative effectiveness of rituximab- versus cyclophosphamide-based remission induction strategies in Antineutrophil cytoplasmic antibody-associated Vasculitis for the risk of kidney failure and mortality","volume":"75","author":"Wallace","year":"2023","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.autrev.2025.103894_bb0045","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1136\/ard-2023-224472","article-title":"Short-term effectiveness and safety of rituximab versus cyclophosphamide for life-threatening ANCA-associated vasculitis: a propensity score analysis of the real-world nationwide database","volume":"83","author":"Ishikawa","year":"2024","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.autrev.2025.103894_bb0050","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1093\/ndt\/gfr127","article-title":"Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis","volume":"26","author":"Mansfield","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"issue":"1","key":"10.1016\/j.autrev.2025.103894_bb0055","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/ndt\/gfx378","article-title":"Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis [published correction appears in Nephrol dial transplant. 2018 may 1;33(5):899. Doi: 10.1093\/ndt\/gfy075.]","volume":"34","author":"McAdoo","year":"2019","journal-title":"Nephrol. Dial. Transplant."},{"issue":"6","key":"10.1016\/j.autrev.2025.103894_bb0060","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.kint.2021.08.025","article-title":"Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis","volume":"100","author":"Gulati","year":"2021","journal-title":"Kidney Int."},{"key":"10.1016\/j.autrev.2025.103894_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ekir.2025.04.030","article-title":"Combination cyclophosphamide and rituximab to minimize glucocorticoid use in antineutrophil cytoplasm antibody\u2013associated vasculitis","author":"Salehi","year":"2025","journal-title":"Kidney Int Rep"},{"issue":"5","key":"10.1016\/j.autrev.2025.103894_bb0505","first-page":"814","article-title":"Combination therapy with rituximab and cyclophosphamide for remission induction in ANCA vasculitis","volume":"2","author":"Cortazar","year":"2017","journal-title":"Kidney Int Rep."},{"issue":"4","key":"10.1016\/j.autrev.2025.103894_bb0510","first-page":"928","article-title":"ANCA-associated pulmonary-renal syndrome treated with cyclophosphamide, rituximab, repeated methyl-prednisolone pulses and a reduced oral glucocorticoid regime: an observational study","volume":"41","author":"G\u00f3mez-Carballo","year":"2023","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.autrev.2025.103894_bb0070","doi-asserted-by":"crossref","first-page":"i123","DOI":"10.1093\/ndt\/gfv076","article-title":"Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"30 Suppl 1(Suppl 1)","author":"McGregor","year":"2015","journal-title":"Nephrol. Dial. Transplant."},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2025.103894_bb0075","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1136\/annrheumdis-2023-eular.3867","article-title":"POS1161: rituximab vs. combination of rituximab and cyclophosphamide induction therapy for ANCA-associated vasculitis: a retrospective study [abstract]","volume":"82","author":"Von Allw\u00f6rden","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.autrev.2025.103894_bb0080","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-061339","article-title":"ExploriNg DUrable remission with rituximab in ANCA-associatEd vasculitis (ENDURRANCE trial): protocol for a randomised controlled trial","volume":"12","author":"Dirikgil","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.autrev.2025.103894_bb0085","series-title":"A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis published correction appears in Rheumatology (Oxford)","first-page":"373","volume":"58(2)","author":"Pepper","year":"2019"},{"issue":"8","key":"10.1016\/j.autrev.2025.103894_bb0090","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/annrheumdis-2017-212768","article-title":"Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides","volume":"77","author":"Terrier","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.autrev.2025.103894_bb0095","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1136\/annrheumdis-2017-211123","article-title":"Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis","volume":"76","author":"Karras","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.autrev.2025.103894_bb0100","doi-asserted-by":"crossref","first-page":"947","DOI":"10.7326\/L20-1198","article-title":"Long-term rituximab use to maintain remission of Antineutrophil cytoplasmic antibody-associated Vasculitis","volume":"173","author":"Garvey","year":"2020","journal-title":"Ann. Intern. Med."},{"issue":"6","key":"10.1016\/j.autrev.2025.103894_bb0105","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","article-title":"2019 update of the joint European league against rheumatism and European renal association-European Dialysis and transplant association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis","volume":"79","author":"Fanouriakis","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.autrev.2025.103894_bb0110","doi-asserted-by":"crossref","DOI":"10.1002\/acr.25507","article-title":"Lupus flares: more common in dialysis patients than in post-kidney transplant recipients: a systematic review and meta-analysis","author":"Daoud","year":"2025","journal-title":"Arthritis Care Res."},{"issue":"6","key":"10.1016\/j.autrev.2025.103894_bb0115","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/ndt\/gfad237","article-title":"ANCA-associated vasculitis-treatment standard","volume":"39","author":"Chalkia","year":"2024","journal-title":"Nephrol. Dial. Transplant."},{"issue":"2","key":"10.1016\/j.autrev.2025.103894_bb0120","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.33361","article-title":"Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"64","author":"Walsh","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2025.103894_bb0125","doi-asserted-by":"crossref","first-page":"i150","DOI":"10.1093\/ndt\/gfu397","article-title":"Maintenance therapy in antineutrophil cytoplasmic antibody-associated vasculitis: who needs what and for how long?","volume":"30","author":"de Joode","year":"2015","journal-title":"Nephrol. Dial. Transplant."},{"issue":"4","key":"10.1016\/j.autrev.2025.103894_bb0130","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1093\/rheumatology\/keae409","article-title":"Relapses and serious adverse events during rituximab maintenance therapy in ANCA-associated vasculitis: a multicentre retrospective study","volume":"64","author":"Gialouri","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2025.103894_bb0135","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2215\/CJN.06460622","article-title":"Maintenance of remission and risk of relapse in myeloperoxidase-positive ANCA-associated Vasculitis with kidney involvement","volume":"18","author":"Casal Moura","year":"2023","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"5","key":"10.1016\/j.autrev.2025.103894_bb0140","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/RHU.0000000000001030","article-title":"Evaluation of PR3-ANCA status after rituximab for ANCA-associated Vasculitis","volume":"25","author":"McClure","year":"2019","journal-title":"J. Clin. Rheumatol."},{"issue":"8","key":"10.1016\/j.autrev.2025.103894_bb0145","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.ekir.2022.05.018","article-title":"The sound of interconnectivity; the European Vasculitis Society 2022 report","volume":"7","author":"Egan","year":"2022","journal-title":"Kidney Int Rep."},{"issue":"19","key":"10.1016\/j.autrev.2025.103894_bb0150","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.autrev.2025.103894_bb0155","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/ard-2022-223559","article-title":"Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial","volume":"82","author":"Smith","year":"2023","journal-title":"Ann. Rheum. Dis."},{"issue":"21","key":"10.1016\/j.autrev.2025.103894_bb0160","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1001\/jama.2021.6615","article-title":"Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated Vasculitis: a randomized clinical trial","volume":"325","author":"Furuta","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.autrev.2025.103894_bb0165","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1136\/ard-2023-224343","article-title":"Reduced-dose versus high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: predefined 2-year follow-up study","volume":"83","author":"Furuta","year":"2024","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.autrev.2025.103894_bb0170","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.autrev.2025.103894_bb0175","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/acr.25045","article-title":"2022 American College of Rheumatology Guideline for vaccinations in patients with rheumatic and musculoskeletal diseases","volume":"75","author":"Bass","year":"2023","journal-title":"Arthritis Care Res."},{"issue":"3","key":"10.1016\/j.autrev.2025.103894_bb0180","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host [published correction appears in Clin infect dis. 2014 Jul 1;59(1):144]","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin. Infect. Dis."},{"issue":"9","key":"10.1016\/j.autrev.2025.103894_bb0185","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of C5a receptor inhibitor Avacopan in ANCA-associated Vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"issue":"11","key":"10.1016\/j.autrev.2025.103894_bb0190","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/acr2.11185","article-title":"Adjunctive treatment with Avacopan, an Oral C5a receptor inhibitor, in patients with Antineutrophil cytoplasmic antibody-associated Vasculitis","volume":"2","author":"Merkel","year":"2020","journal-title":"ACR Open Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2025.103894_bb0195","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"ADVOCATE study group. Avacopan for the treatment of ANCA-associated Vasculitis [published correction appears in N Engl J med. 2024 Jan 25;390(4):388. Doi: 10.1056\/NEJMx230010.]","volume":"384","author":"Jayne","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.autrev.2025.103894_bb0200","doi-asserted-by":"crossref","first-page":"e451","DOI":"10.1016\/S2665-9913(23)00092-9","article-title":"The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial","volume":"5","author":"Strand","year":"2023","journal-title":"Lancet Rheumatol."},{"issue":"4","key":"10.1016\/j.autrev.2025.103894_bb0205","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.ekir.2023.01.039","article-title":"Renal recovery for patients with ANCA-associated Vasculitis and low eGFR in the ADVOCATE trial of Avacopan","volume":"8","author":"Cortazar","year":"2023","journal-title":"Kidney Int Rep."},{"issue":"9","key":"10.1016\/j.autrev.2025.103894_bb0210","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1093\/ndt\/gfae020","article-title":"Avacopan for ANCA-associated vasculitis with hypoxic pulmonary haemorrhage","volume":"39","author":"Chalkia","year":"2024","journal-title":"Nephrol. Dial. Transplant."},{"issue":"3","key":"10.1016\/j.autrev.2025.103894_bb0215","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ekir.2021.11.036","article-title":"Compassionate use of Avacopan in difficult-to-treat Antineutrophil cytoplasmic antibody-associated Vasculitis","volume":"7","author":"van Leeuwen","year":"2021","journal-title":"Kidney Int Rep."},{"issue":"2","key":"10.1016\/j.autrev.2025.103894_bb0220","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/14737167.2023.2297790","article-title":"A projected cost-utility analysis of avacopan for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis in Spain","volume":"24","author":"Mac\u00eda","year":"2024","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"issue":"12","key":"10.1016\/j.autrev.2025.103894_bb0225","doi-asserted-by":"crossref","first-page":"S157","DOI":"10.1016\/j.jval.2022.09.760","article-title":"EE519 cost effectiveness analysis of avacopan in antineutrophil cytoplasm antibody-associated vasculitis\u2014a Canadian perspective","volume":"25","author":"Lakhdari","year":"2022","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.autrev.2025.103894_bb0230","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.ekir.2022.01.1065","article-title":"Avacopan as first-line treatment in Antineutrophil cytoplasmic antibody-associated Vasculitis: a steroid-sparing option","volume":"7","author":"Gabilan","year":"2022","journal-title":"Kidney Int Rep."},{"issue":"6","key":"10.1016\/j.autrev.2025.103894_bb0235","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.ekir.2024.03.022","article-title":"Real-world experience with Avacopan in Antineutrophil cytoplasmic autoantibody-associated Vasculitis","volume":"9","author":"Zonozi","year":"2024","journal-title":"Kidney Int Rep."},{"issue":"4","key":"10.1016\/j.autrev.2025.103894_bb0240","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1093\/rheumatology\/keae534","article-title":"The real-world use and effectiveness of avacopan in routine practice for the treatment of ANCA vasculitis. First experiences in Spain","volume":"64","author":"Draibe","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.autrev.2025.103894_bb0245","article-title":"Is it possible to use avacopan alone in the induction of remission in ANCA-associated vasculitis?","volume":"8","author":"Kubota","year":"2024","journal-title":"Rheumatol Adv Pract"},{"issue":"4","key":"10.1016\/j.autrev.2025.103894_bb0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195680","article-title":"Hypocomplementemia is associated with worse renal survival in ANCA-positive granulomatosis with polyangiitis and microscopic polyangiitis","volume":"13","author":"Deshayes","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.autrev.2025.103894_bb0255","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1080\/0886022X.2020.1803086","article-title":"Hypocomplementemia is associated with more severe renal disease and worse renal outcomes in patients with ANCA-associated vasculitis: a retrospective cohort study","volume":"42","author":"Chalkia","year":"2020","journal-title":"Ren. Fail."},{"issue":"7","key":"10.1016\/j.autrev.2025.103894_bb0260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158871","article-title":"Low Serum Complement C3 Levels at Diagnosis of Renal ANCA-Associated Vasculitis Is Associated with Poor Prognosis","volume":"11","author":"Augusto","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.autrev.2025.103894_bb0265","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ekir.2022.10.033","article-title":"Tailored use of Avacopan in a case with refractory Antineutrophil cytoplasmic antibody-associated renal Vasculitis and Concominant complement system activation","volume":"8","author":"Hakroush","year":"2022","journal-title":"Kidney Int Rep."},{"issue":"5","key":"10.1016\/j.autrev.2025.103894_bb0270","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1093\/rheumatology\/keae689","article-title":"Drug-induced liver injury related to avacopan therapy","volume":"64","author":"Mori","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.autrev.2025.103894_bb0275","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1093\/rheumatology\/kead509","article-title":"Severe prolonged liver abnormality with jaundice during treatment for granulomatosis with polyangiitis with rituximab and avacopan","volume":"63","author":"Kojima","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.autrev.2025.103894_bb0280","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1093\/mrcr\/rxad019","article-title":"Gradual increase of avacopan dose with concomitant ursodeoxycholic acid use may help avoid the risk of C5a receptor inhibitor-induced liver injury in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"7","author":"Kataoka","year":"2023","journal-title":"Mod Rheumatol Case Rep"},{"issue":"4","key":"10.1016\/j.autrev.2025.103894_bb0285","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1093\/rheumatology\/kead285","article-title":"A case of vanishing bile duct syndrome during treatment of microscopic polyangiitis with avacopan","volume":"63","author":"Yamaguchi","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103894_bb0290","article-title":"Absence of glucocorticoids concomitant with Avacopan and subsequent liver injury in Antineutrophil cytoplasmic antibody-associated Vasculitis","volume":"51(11):1151","author":"Uchida","year":"2024","journal-title":"J. Rheumatol."},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2025.103894_bb0295","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1136\/annrheumdis-2024-eular.442","article-title":"AB1241: design of AVACOSTAR: a real-world study of avacopan in ANCA-associated vasculitis (AAV) [abstract]","volume":"83","author":"Jayne","year":"2024","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.autrev.2025.103894_bb0300","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2007010090","article-title":"Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis","volume":"18","author":"Jayne","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"issue":"2","key":"10.1016\/j.autrev.2025.103894_bb0305","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/ki.2013.131","article-title":"Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear","volume":"84","author":"Walsh","year":"2013","journal-title":"Kidney Int."},{"issue":"22","key":"10.1016\/j.autrev.2025.103894_bb0310","first-page":"2169","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated Vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"Reply N Engl J Med"},{"issue":"3","key":"10.1016\/j.autrev.2025.103894_bb0315","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.kint.2024.11.029","article-title":"The effects of plasma exchange and glucocorticoids on early kidney function among patients with ANCA-associated vasculitis in the PEXIVAS trial","volume":"107","author":"Odler","year":"2025","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.autrev.2025.103894_bb0320","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13075-021-02415-z","article-title":"Efficacy of plasma exchange for antineutrophil cytoplasmic antibody-associated systemic vasculitis: a systematic review and meta-analysis","volume":"23","author":"Yamada","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.autrev.2025.103894_bb0325","doi-asserted-by":"crossref","first-page":"312","DOI":"10.5414\/CN110410","article-title":"The therapeutic effect of plasma exchange on ANCA-associated vasculitis: a meta-analysis","volume":"95","author":"Zhu","year":"2021","journal-title":"Clin. Nephrol."},{"key":"10.1016\/j.autrev.2025.103894_bb0330","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-064604","article-title":"The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis","volume":"376","author":"Walsh","year":"2022","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.autrev.2025.103894_bb0335","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1164\/rccm.202308-1426OC","article-title":"Alveolar hemorrhage in Antineutrophil cytoplasmic antibody-associated Vasculitis: results of an international randomized controlled trial (PEXIVAS)","volume":"209","author":"Fussner","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"Suppl. 9","key":"10.1016\/j.autrev.2025.103894_bb0340","article-title":"Plasma exchange for severe alveolar hemorrhage in ANCA-associated vasculitis: emulation of a target trial [abstract]. Arthritis","volume":"76","author":"Sanna","year":"2024","journal-title":"Rheumatol"},{"key":"10.1016\/j.autrev.2025.103894_bb0345","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.34067\/KID.0005052021","article-title":"Learning methodological lessons from exemplar studies in nephrology: PEXIVAS and Sample Size Calculation","volume":"360","author":"Sandys","year":"2022","journal-title":"Kidney"},{"issue":"2","key":"10.1016\/j.autrev.2025.103894_bb0350","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/ndt\/gfaa311","article-title":"Plasma exchange in ANCA-associated vasculitis: the pro position","volume":"36","author":"Kronbichler","year":"2021","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.autrev.2025.103894_bb0355","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-064597","article-title":"Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis: a clinical practice guideline","volume":"376","author":"Zeng","year":"2022","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.autrev.2025.103894_bb0515","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/ndt\/gfq360","article-title":"Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener\u2019s granulomatosis--a clinical randomized controlled trial","volume":"26","author":"Szpirt","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"issue":"6","key":"10.1016\/j.autrev.2025.103894_bb0520","first-page":"1467","article-title":"Diffuse alveolar hemorrhage secondary to Antineutrophil cytoplasmic antibody-associated Vasculitis: predictors of respiratory failure and clinical outcomes [published correction appears in arthritis Rheumatol. 2016 Sep;68(9):2140. Doi: 10.1002\/art.39823.]","volume":"68","author":"Cartin-Ceba","year":"2016","journal-title":"Arthritis Rheum."},{"issue":"10","key":"10.1016\/j.autrev.2025.103894_bb0360","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1016\/j.ekir.2021.08.002","article-title":"Clinical practice audit on the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in the Netherlands","volume":"6","author":"Dirikgil","year":"2021","journal-title":"Kidney Int Rep."},{"issue":"2","key":"10.1016\/j.autrev.2025.103894_bb0365","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/ard-2024-226339","article-title":"Real-life use of the PEXIVAS reduced-dose glucocorticoid regimen in granulomatosis with polyangiitis and microscopic polyangiitis","volume":"84","author":"Nagle","year":"2025","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.autrev.2025.103894_bb0370","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1016\/j.ekir.2025.03.009","article-title":"Long-term follow-up of a glucocorticoid minimizing regimen for the treatment of severe antineutrophil cytoplasmic autoantibody\u2013associated vasculitis","volume":"10","author":"McAdoo","year":"2025","journal-title":"Kidney Int Rep."},{"key":"10.1016\/j.autrev.2025.103894_bb0375","article-title":"Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis: a multi-center retrospective cohort study","volume":"20(1):58","author":"Chanouzas","year":"2019","journal-title":"BMC Nephrol."},{"issue":"2","key":"10.1016\/j.autrev.2025.103894_bb0380","doi-asserted-by":"crossref","first-page":"240","DOI":"10.2215\/CJN.05610611","article-title":"Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease","volume":"7","author":"McGregor","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"9","key":"10.1016\/j.autrev.2025.103894_bb0385","doi-asserted-by":"crossref","first-page":"e1286","DOI":"10.34067\/KID.0000000000000222","article-title":"Low-dose intravenous methylprednisolone in remission induction therapy for ANCA-associated Vasculitis","volume":"4","author":"Floyd","year":"2023","journal-title":"Kidney360"},{"issue":"9","key":"10.1016\/j.autrev.2025.103894_bb0390","doi-asserted-by":"crossref","first-page":"e1199","DOI":"10.34067\/KID.0000000000000257","article-title":"Intravenous methylprednisolone in induction therapy for ANCA-associated Vasculitis: how low can we go?","volume":"4","author":"Oliva-Damaso","year":"2023","journal-title":"Kidney360"},{"issue":"8","key":"10.1016\/j.autrev.2025.103894_bb0395","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","volume":"77","author":"Charles","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.autrev.2025.103894_bb0400","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/acr.20176","article-title":"Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis","volume":"62","author":"Walsh","year":"2010","journal-title":"Arthritis Care Res."},{"issue":"Suppl. 9","key":"10.1016\/j.autrev.2025.103894_bb0405","article-title":"A multicenter, randomized, controlled trial to evaluate the effects of low-dose glucocorticoids compared to stopping glucocorticoids to maintain remission of granulomatosis with polyangiitis: the TAPIR trial [abstract]. Arthritis","volume":"76","author":"Merkel","year":"2024","journal-title":"Rheumatol"},{"issue":"9","key":"10.1016\/j.autrev.2025.103894_bb0525","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1136\/annrheumdis-2019-216863","article-title":"Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis","volume":"79","author":"Smith","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.autrev.2025.103894_bb0410","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003113","article-title":"Diagnostic significance of antineutrophil cytoplasmic antibody (ANCA) titres: a retrospective case-control study","volume":"9","author":"Merindol","year":"2023","journal-title":"RMD Open"},{"issue":"9","key":"10.1016\/j.autrev.2025.103894_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102618","article-title":"2020 international consensus on ANCA testing beyond systemic vasculitis","volume":"19","author":"Moiseev","year":"2020","journal-title":"Autoimmun. Rev."},{"issue":"3","key":"10.1016\/j.autrev.2025.103894_bb0420","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1681\/ASN.2013111233","article-title":"ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal disease","volume":"26","author":"Kemna","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"issue":"7","key":"10.1016\/j.autrev.2025.103894_bb0425","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1002\/art.39637","article-title":"Factors determining the clinical utility of serial measurements of Antineutrophil cytoplasmic antibodies targeting proteinase 3","volume":"68","author":"Fussner","year":"2016","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2025.103894_bb0430","doi-asserted-by":"crossref","first-page":"844112","DOI":"10.3389\/fmed.2022.844112","article-title":"Do relapses follow anca rises? A systematic review and meta-analysis on the value of serial ANCA level evaluation","volume":"9","author":"Al-Soudi","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"12","key":"10.1016\/j.autrev.2025.103894_bb0435","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2018-214486","article-title":"\u2018MAINRITSAN2-the future\u2019, with some doubts!","volume":"78","author":"Chattopadhyay","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"12","key":"10.1016\/j.autrev.2025.103894_bb0440","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2018-214516","article-title":"Response to: MAINRITSAN2-the future, with some doubts! By Chattopadhyay et al","volume":"78","author":"Charles","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.autrev.2025.103894_bb0445","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/ard-2023-224623","article-title":"Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials","volume":"83","author":"Delestre","year":"2024","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.autrev.2025.103894_bb0450","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/M19-3827","article-title":"Long-term rituximab use to maintain remission of Antineutrophil cytoplasmic antibody-associated Vasculitis: a randomized trial","volume":"173","author":"Charles","year":"2020","journal-title":"Ann. Intern. Med."},{"issue":"7","key":"10.1016\/j.autrev.2025.103894_bb0455","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/rheumatology\/keu452","article-title":"Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis","volume":"54","author":"Alberici","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.autrev.2025.103894_bb0460","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard-2023-224489","article-title":"Maintenance of remission of ANCA vasculitis by rituximab based on B cell repopulation versus serological flare: a randomised trial","volume":"83","author":"Zonozi","year":"2024","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.autrev.2025.103894_bb0465","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/rheumatology\/ker280","article-title":"Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis","volume":"51","author":"Tomasson","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.autrev.2025.103894_bb0470","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1093\/ndt\/gfr109","article-title":"Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy","volume":"26","author":"Roccatello","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"issue":"12","key":"10.1016\/j.autrev.2025.103894_bb0475","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.autrev.2015.07.017","article-title":"A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment-clinical response compared to literature and immunological re-assessment","volume":"14","author":"Roccatello","year":"2015","journal-title":"Autoimmun. Rev."},{"issue":"2","key":"10.1016\/j.autrev.2025.103894_bb0480","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3390\/jcm10020292","article-title":"A 3-Year Observational Study of Patients with Progressive Systemic Sclerosis Treated with an Intensified B Lymphocyte Depletion Protocol: Clinical and Immunological Response","volume":"10","author":"Rossi","year":"2021","journal-title":"J. Clin. Med."},{"issue":"4","key":"10.1016\/j.autrev.2025.103894_bb0485","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.ekir.2021.01.027","article-title":"A prospective study on long-term clinical outcomes of patients with lupus nephritis treated with an intensified B-cell depletion protocol without maintenance therapy","volume":"6","author":"Roccatello","year":"2021","journal-title":"Kidney Int Rep."},{"key":"10.1016\/j.autrev.2025.103894_bb0490","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.777134","article-title":"Treating patients with ANCA-associated Vasculitis and very severe renal injury with an intensified B cell depletion therapy: comparison with a control cohort receiving a conventional therapy","volume":"13","author":"Roccatello","year":"2022","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.autrev.2025.103894_bb0495","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/j.ard.2025.01.008","article-title":"Anti-CD19 CAR T cell therapy induces antibody seroconversion and complete B cell depletion in the bone marrow of a therapy-refractory patient with ANCA-associated vasculitis","volume":"84","author":"Minopoulou","year":"2025","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.autrev.2025.103894_bb0500","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/ard-2024-226142","article-title":"CD19-CAR T-cell therapy induces deep tissue depletion of B cells","volume":"84","author":"Tur","year":"2025","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.autrev.2025.103894_bb0530","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/rheumatology\/key428","article-title":"Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis","volume":"58","author":"Ramwadhdoebe","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2025.103894_bb0535","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2215\/CJN.09430915","article-title":"B cells, antibodies, and more","volume":"11","author":"Hoffman","year":"2016","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.autrev.2025.103894_bb0540","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1186\/ar1688","article-title":"The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis","volume":"7 Suppl 2(Suppl 2)","author":"Ruderman","year":"2005","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"10.1016\/j.autrev.2025.103894_bb0545","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1002\/art.11299","article-title":"Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator","volume":"48","author":"Baker","year":"2003","journal-title":"Arthritis Rheum."},{"issue":"7","key":"10.1016\/j.autrev.2025.103894_bb0550","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-083277","article-title":"Study protocol for a randomised, phase II, double-blind, experimental medicine study of obinutuzumab versus rituximab in ANCA-associated vasculitis: ObiVas","volume":"14","author":"McGovern","year":"2024","journal-title":"BMJ Open"},{"issue":"8","key":"10.1016\/j.autrev.2025.103894_bb0560","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/rheumatology\/kew199","article-title":"Ofatumumab for B cell depletion therapy in ANCA-associated vasculitis: a single-Centre case series","volume":"55","author":"McAdoo","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.autrev.2025.103894_bb0565","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/art.40802","article-title":"Efficacy and safety of Belimumab and azathioprine for maintenance of remission in Antineutrophil cytoplasmic antibody-associated Vasculitis: a randomized controlled study","volume":"71","author":"Jayne","year":"2019","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2025.103894_bb0575","article-title":"A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol","volume":"24(1):180","author":"McClure","year":"2023","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.autrev.2025.103894_bb0580","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002742","article-title":"Daratumumab for the treatment of refractory ANCA-associated vasculitis","volume":"9","author":"Ostendorf","year":"2023","journal-title":"RMD Open"},{"issue":"6","key":"10.1016\/j.autrev.2025.103894_bb0585","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/jamainternmed.2023.0152","article-title":"Daratumumab for a patient with refractory Antineutrophil Cytoplasmatic antibody-associated Vasculitis","volume":"183","author":"Rixecker","year":"2023","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.autrev.2025.103894_bb0615","doi-asserted-by":"crossref","DOI":"10.1002\/art.43272","article-title":"A randomized, double-blind, placebo-controlled trial of abatacept for the treatment of relapsing, non-severe, granulomatosis with polyangiitis","author":"Langford","year":"2025","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.autrev.2025.103894_bb0625","doi-asserted-by":"crossref","first-page":"8220","DOI":"10.1038\/s41467-024-52525-w","article-title":"Immune profiling-based targeting of pathogenic T cells with ustekinumab in ANCA-associated glomerulonephritis","volume":"15","author":"Engesser","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.autrev.2025.103894_bb0620","article-title":"Alemtuzumab for refractory primary systemic vasculitis-a randomised controlled dose ranging clinical trial of efficacy and safety (ALEVIATE)","volume":"24(1):81","author":"Gopaluni","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2025.103894_bb0665","article-title":"The effect of intranasal niclosamide on nasal symptoms in patients with ENT manifestations of ANCA-associated vasculitis (AAV): post hoc analysis of subset of patients recruited to the PROTECT-V trial. Arthritis","volume":"76(Suppl 9):Abstract","author":"Lim","year":"2024","journal-title":"Rheumatol"},{"issue":"9","key":"10.1016\/j.autrev.2025.103894_bb0555","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1093\/rheumatology\/keab916","article-title":"Obinutuzumab as treatment for ANCA-associated vasculitis","volume":"61","author":"Amudala","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.autrev.2025.103894_bb0570","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41584-018-0065-x","article-title":"B cell therapy in ANCA-associated vasculitis: current and emerging treatment options [published correction appears in Nat rev Rheumatol. 2018 Dec;14(12):741. Doi: 10.1038\/s41584-018-0116-3.]","volume":"14","author":"McClure","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"issue":"6","key":"10.1016\/j.autrev.2025.103894_bb0590","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.autrev.2025.103894_bb0595","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune Disease - a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.autrev.2025.103894_bb0600","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/ard-2023-224875","article-title":"CD19-targeting CAR T cells protect from ANCA-induced acute kidney injury","volume":"83","author":"Lodka","year":"2024","journal-title":"Ann. Rheum. Dis."},{"issue":"Suppl. 9","key":"10.1016\/j.autrev.2025.103894_bb0605","article-title":"Safety and long-term efficacy of CD19-CAR T-cell therapy in 30 patients with autoimmune disease [abstract]. Arthritis","volume":"76","author":"Hagen","year":"2024","journal-title":"Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2025.103894_bb0610","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1136\/annrheumdis-2013-204164","article-title":"An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener\u2019s)","volume":"73","author":"Langford","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.autrev.2025.103894_bb0630","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/rheumatology\/ket284","article-title":"Efficacy and tolerability of repeated cycles of a once-weekly regimen of bortezomib in lupus","volume":"53","author":"Quartuccio","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103894_bb0635","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1177\/0961203316686703","article-title":"The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis","volume":"26","author":"Zhang","year":"2017","journal-title":"Lupus"},{"issue":"7","key":"10.1016\/j.autrev.2025.103894_bb0640","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1136\/annrheumdis-2014-206016","article-title":"The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus","volume":"74","author":"Alexander","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.autrev.2025.103894_bb0645","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1681\/ASN.2010010034","article-title":"Myeloperoxidase-specific plasma cell depletion by bortezomib protects from anti-neutrophil cytoplasmic autoantibodies-induced glomerulonephritis","volume":"22","author":"Bontscho","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.autrev.2025.103894_bb0650","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2015-207947","article-title":"Bortezomib in refractory ANCA-associated vasculitis: a new option?","volume":"75","author":"Novikov","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.autrev.2025.103894_bb0655","doi-asserted-by":"crossref","first-page":"6519","DOI":"10.1038\/s41467-024-50747-6","article-title":"Cathepsin C inhibition reduces neutrophil serine protease activity and improves activated neutrophil-mediated disorders","volume":"15","author":"Nishibata","year":"2024","journal-title":"Nat. Commun."},{"issue":"22","key":"10.1016\/j.autrev.2025.103894_bb0660","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.autrev.2025.103894_bb0670","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106311","article-title":"Ravulizumab and other complement inhibitors for the treatment of autoimmune disorders","volume":"95","author":"Vieira","year":"2025","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"10.1016\/j.autrev.2025.103894_bb0675","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s11739-017-1636-6","article-title":"Complement blockade in ANCA-associated vasculitis: an index case, current concepts and future perspectives","volume":"12","author":"Manenti","year":"2017","journal-title":"Intern. Emerg. Med."},{"issue":"12","key":"10.1016\/j.autrev.2025.103894_bb0680","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1093\/rheumatology\/kez190","article-title":"Glucocorticoid-free induction regimen in severe ANCA-associated vasculitis using a combination of rituximab and eculizumab","volume":"58","author":"Ribes","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"10S","key":"10.1016\/j.autrev.2025.103894_bb0685","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1681\/ASN.20213210S1824a","article-title":"Complement inhibition with a short course of eculizumab for refractory vasculitis: PUB211","volume":"32","author":"Rivera","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/j.autrev.2025.103894_bb0690","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/cei.13498","article-title":"The alternative complement pathway in ANCA-associated vasculitis: further evidence and a meta-analysis","volume":"202","author":"Moiseev","year":"2020","journal-title":"Clin. Exp. Immunol."},{"issue":"3","key":"10.1016\/j.autrev.2025.103894_bb0695","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","article-title":"Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology","volume":"16","author":"Schrezenmeier","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"issue":"5","key":"10.1016\/j.autrev.2025.103894_bb0700","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.kint.2022.07.026","article-title":"Arterial stiffness, endothelial dysfunction and impaired fibrinolysis are pathogenic mechanisms contributing to cardiovascular risk in ANCA-associated vasculitis","volume":"102","author":"Farrah","year":"2022","journal-title":"Kidney Int."},{"issue":"5","key":"10.1016\/j.autrev.2025.103894_bb0705","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.kint.2022.08.029","article-title":"Endothelium and endothelin: regulators of arterial stiffness and fibrinolysis in ANCA-associated vasculitis","volume":"102","author":"Barton","year":"2022","journal-title":"Kidney Int."}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225001557?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225001557?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T23:53:03Z","timestamp":1763769183000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997225001557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":141,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1568997225001557"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103894","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Points to consider in the management of ANCA-associated vasculitis","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103894","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103894"}}